text
"['\nX. 대주주 등과의 거래내용\n(1) 당분기 및 전분기 중 회사와 매출 등 거래 또는 채권, 채무 잔액이 있는 특수관계자 현황은 다음과 같습니다.\n관 계\n회\xa0 \xa0\xa0 사\xa0 \xa0\xa0 명\n종속기업\n\xa0㈜유한화학, ㈜유한메디카, ㈜엠지, ㈜유한건강생활, 애드파마㈜, YUHAN USA CORPORATION, YUHAN UZBEKISTAN\n관계기업 및 공동기업\n\xa0유한킴벌리㈜, ㈜유한크로락스, ㈜유칼릭스, ㈜한국얀센, ㈜이뮨온시아, ㈜씨.앤.씨, ㈜아임뉴런바이오사이언스, ㈜워랜텍, 인도 G.T.B.L, ㈜지아이이노베이션, ㈜휴이노, 아말로이드솔루션㈜, ㈜지아이바이옴, ㈜메디오젠, ㈜에이프릴바이오, ㈜테라베스트, ㈜성보펫헬스케어, ㈜네오딘바이오벳, 주노랩㈜\n기타특수관계자\n\xa0㈜리드팜, ㈜내츄럴엔도텍, 류신(칭다오)건강(유), ㈜유앤생명과학\n(2) 당분기 및 전분기 중 특수관계자와의 거래 내역은 다음과 같습니다.\n- 당분기\n\xa0(단위:천원)\n특수관계자의 명칭\n제상품매출\n임대, 용역수익\n기타(잡이익등)\n배당금수익\n매입등\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n(종속기업)\n\xa0㈜유한화학\xa0\n1,910\n3,710\n-\n-\n-\n-\n-\n-\n43,197,142\n112,532,360\n\xa0㈜유한메디카\n1,455\n2,909\n6,900\n20,700\n-\n29,878\n-\n-\n35,555,272\n35,555,272\n\xa0㈜엠지\n-\n-\n8,970\n26,910\n-\n-\n-\n-\n3,929,539\n9,265,690\n\xa0㈜유한건강생활\n-\n-\n268,368\n869,672\n105,554\n117,284\n-\n-\n2,693,818\n8,128,326\n\xa0애드파마㈜\n-\n-\n1,560\n33,076\n-\n5,000\n-\n-\n2,173,818\n8,216,477\n소 계\n3,365\n6,619\n285,798\n950,358\n105,554\n152,162\n-\n-\n87,549,589\n173,698,125\n(관계기업 및 공동기업)\n㈜유칼릭스\n-\n-\n-\n-\n-\n-\n-\n40,800\n15,302\n46,426\n㈜유한크로락스\n-\n-\n445,231\n1,233,996\n-\n-\n-\n2,747,500\n21,469,328\n54,891,008\n유한킴벌리㈜\n-\n-\n-\n-\n-\n-\n-\n19,500,000\n71,238\n777,018\n㈜한국얀센\n-\n-\n204,661\n386,623\n-\n-\n-\n-\n9,155,232\n27,954,479\n㈜이뮨온시아\n-\n-\n936\n2,808\n900\n2,700\n-\n-\n-\n-\n㈜씨.앤.씨\xa0\n-\n-\n-\n-\n-\n-\n-\n-\n1,473,434\n4,600,743\n㈜워랜텍\n-\n-\n-\n-\n-\n26,782\n-\n-\n518,225\n940,558\n㈜메디오젠\n-\n-\n-\n-\n-\n-\n-\n234,570\n5,021,194\n5,510,657\n㈜지아이이노베이션\n-\n-\n-\n-\n-\n-\n-\n-\n5,500,000\n5,500,000\n㈜네오딘바이오벳\n-\n-\n-\n-\n-\n-\n-\n-\n50,000\n50,000\n㈜성보펫헬스케어\n-\n-\n-\n-\n-\n-\n-\n-\n2,169,128\n2,169,128\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0 소 계\n-\n-\n650,828\n1,623,427\n900\n29,482\n-\n22,522,870\n45,443,081\n102,440,017\n(기타특수관계자)\n\xa0㈜리드팜\n646,357\n1,915,607\n-\n-\n-\n-\n-\n-\n1,910\n5,392\n\xa0㈜내츄럴엔도텍\n-\n-\n-\n-\n-\n-\n-\n2\n-\n31,863\n\xa0류신(칭다오)건강(유)\n-\n-\n-\n-\n-\n-\n-\n-\n1,568\n1,568\n\xa0㈜유앤생명과학\n-\n-\n-\n-\n-\n-\n-\n-\n76,595\n76,595\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0 소 계\n646,357\n1,915,607\n-\n-\n-\n-\n-\n2\n80,073\n115,418\n합 계\xa0\n649,722\n1,922,226\n936,626\n2,573,785\n106,454\n181,644\n-\n22,522,872\n133,072,743\n276,253,560\n- 전분기\n\xa0(단위:천원)\n특수관계자의 명칭\n제상품매출\n임대, 용역수익\n기타(잡이익등)\n배당금수익\n매입등\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n(종속기업)\n\xa0㈜유한화학\xa0\n3,600\n5,400\n-\n-\n-\n-\n-\n-\n36,687,740\n87,867,543\n\xa0㈜유한메디카\n250\n250\n6,900\n20,700\n-\n51,818\n-\n-\n-\n-\n\xa0㈜엠지\n-\n-\n-\n-\n-\n-\n-\n-\n1,576,447\n1,656,216\n\xa0㈜유한건강생활\n-\n-\n538,389\n1,342,282\n1,960\n162,155\n-\n-\n460,590\n674,786\n\xa0YUHAN UZBEKISTAN\n171,516\n171,516\n-\n-\n-\n-\n-\n-\n-\n-\n\xa0애드파마㈜\n-\n-\n44,164\n112,492\n-\n-\n-\n-\n5,659,837\n15,152,498\n소 계\n175,366\n177,166\n589,453\n1,475,474\n1,960\n213,973\n-\n-\n44,384,614\n105,351,043\n(관계기업 및 공동기업)\n\xa0㈜유칼릭스\n-\n-\n-\n-\n-\n-\n-\n40,800\n28,936\n59,644\n\xa0㈜유한크로락스\n-\n-\n494,521\n1,292,238\n-\n-\n-\n3,846,500\n19,772,511\n51,822,525\n\xa0유한킴벌리㈜\n-\n-\n-\n-\n-\n-\n-\n20,100,000\n1,802,268\n4,197,732\n\xa0㈜한국얀센\n-\n-\n71,200\n213,958\n-\n-\n-\n-\n9,300,811\n28,478,498\n\xa0㈜이뮨온시아\n-\n-\n936\n2,808\n900\n2,700\n-\n-\n-\n500\n\xa0㈜씨.앤.씨\xa0\n-\n-\n-\n-\n-\n-\n-\n-\n1,557,964\n5,301,577\n\xa0㈜아임뉴런바이오사이언스\n-\n-\n-\n-\n-\n-\n-\n-\n-\n1,200,000\n\xa0㈜워랜텍\n-\n-\n-\n-\n-\n-\n-\n-\n376,552\n905,938\n\xa0인도 G.T.B.L\n-\n-\n-\n-\n-\n-\n100,497\n100,497\n-\n-\n\xa0㈜지아이이노베이션\n-\n-\n-\n-\n-\n-\n-\n-\n11,000,000\n11,000,000\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0 소 계\n-\n-\n566,657\n1,509,004\n900\n2,700\n100,497\n24,087,797\n43,839,042\n102,966,414\n(기타특수관계자)\n\xa0㈜리드팜\n990,185\n2,271,071\n-\n-\n-\n-\n-\n-\n-\n834\n합 계\xa0\n1,165,551\n2,448,237\n1,156,110\n2,984,478\n2,860\n216,673\n100,497\n24,087,797\n88,223,656\n208,318,291\n(3)\xa0당분기말과\xa0전기말 현재 특수관계자와의 채권ㆍ채무는 다음과 같습니다.\n\xa0(단위:천원)\n특수관계자 명칭\n매출채권\n매입채무\n미수금 등 기타자산\n예수보증금\n당분기말\n전기말\n당분기말\n전기말\n당분기말\n전기말\n당분기말\n전기말\n(종속기업)\n\xa0㈜유한화학\xa0\n-\n-\n7,777,857\n8,737,830\n133,701\n311,702\n-\n-\n\xa0㈜유한메디카\n-\n-\n-\n-\n-\n403,000\n400,000\n400,000\n\xa0㈜엠지\n-\n-\n2,200,408\n2,085,516\n2,737,260\n2,737,259\n520,000\n-\n\xa0㈜유한건강생활\n126,639\n341,631\n2,192,211\n269,545\n-\n-\n796,800\n2,251,000\n\xa0YUHAN UZBEKISTAN(*)\n-\n171,516\n-\n-\n-\n-\n-\n-\n\xa0애드파마㈜\n-\n-\n111,828\n-\n4,053,121\n3,380,019\n-\n-\n소 계\n126,639\n513,147\n12,282,304\n11,092,891\n6,924,082\n6,831,980\n1,716,800\n2,651,000\n(관계기업 및 공동기업)\n\xa0㈜유칼릭스\n-\n-\n554\n3,029\n-\n-\n-\n-\n\xa0㈜유한크로락스\n489,754\n429,311\n15,519,203\n12,021,324\n-\n-\n-\n-\n\xa0유한킴벌리㈜\n-\n20,093\n41,402\n864,395\n-\n-\n-\n-\n\xa0㈜한국얀센\n180,127\n-\n6,655,976\n4,661,158\n-\n-\n-\n-\n\xa0㈜이뮨온시아\n343\n-\n-\n-\n330\n-\n-\n-\n\xa0㈜씨.앤.씨\n-\n-\n1,127,656\n930,451\n-\n-\n-\n-\n\xa0㈜워랜텍\n-\n-\n397,781\n854,688\n-\n-\n-\n-\n\xa0㈜메디오젠\n-\n-\n3,244,677\n-\n-\n-\n-\n-\n\xa0㈜성보펫헬스케어\n-\n-\n1,589,197\n-\n-\n소 계\n670,224\n449,404\n28,576,446\n19,335,045\n330\n-\n-\n-\n(기타특수관계자)\n\xa0㈜리드팜\n576,558\n507,836\n-\n-\n-\n-\n-\n-\n\xa0㈜유앤생명과학\n-\n-\n84,254\n-\n-\n-\n-\n-\n소 계\n576,558\n507,836\n84,254\n-\n-\n-\n-\n-\n합 계\n1,373,421\n1,470,387\n40,943,004\n30,427,936\n6,924,412\n6,831,980\n1,716,800\n2,651,000\n(*) 당분기말 현재 특수관계자 YUHAN UZBEKISTAN의 매출채권에 대한 대손충당금을 차감한 금액을 계상하고 있습니다.\n(4) 당분기 및 전분기 중 특수관계자와의 자금거래 내역은 다음과 같습니다.\n(단위: 천원)\n특수관계 구분\n회사명\n당분기\n전분기\n대여\n회수\n출자\n대여\n회수\n출자\n종속기업\nYUHAN UZBEKISTAN\n-\n-\n226,360\n-\n-\n120,070\n㈜유한건강생활\n-\n-\n5,438,142\n-\n-\n-\nYUHAN USA CORPORATION\n-\n-\n6,367,400\n-\n-\n3,557,400\n㈜엠지\n-\n-\n21,314,140\n-\n-\n-\n관계기업 및 공동기업\n㈜지아이이노베이션\n-\n-\n9,999,990\n-\n-\n-\n㈜휴이노\n-\n-\n-\n-\n-\n5,000,164\n아말로이드솔루션㈜\n-\n-\n-\n-\n-\n5,000,015\n㈜지아이바이옴\n-\n-\n-\n-\n-\n10,000,010\n㈜메디오젠\n-\n-\n-\n-\n-\n39,876,849\n㈜에이프릴바이오\n-\n-\n10,000,066\n-\n-\n-\n㈜아임뉴런바이오사이언스\n-\n-\n2,000,004\n-\n-\n5,037,000\n㈜테라베스트\n-\n-\n2,999,988\n-\n-\n-\n㈜성보펫헬스케어\n-\n-\n6,999,931\n-\n-\n-\n㈜네오딘바이오벳\n-\n-\n6,499,961\n-\n-\n-\n주노랩㈜\n-\n-\n300,000\n-\n-\n-\n(5) 당분기말 현재 회사가 특수관계자에게 제공한 지급보증 및 담보 내역은 다음과 같습니다.\r\n(단위: 천원)\n특수관계자의 명칭\n보증 등의 내용\n금융기관\n보증 금액\n(종속기업)\n㈜유한건강생활\n운전자금대출\n국민은행\n5,500,000\n㈜유한건강생활\n일반대출\n신한은행\n3,600,000\n애드파마㈜\n운전자금대출\n하나은행\n6,000,000\n합\xa0 계\n15,100,000\n(6) 회사는 등기이사 및 회사 기업활동의 계획, 운영 및 통제에 대한 중요한 권한과 책임을 가진 등기 임원을 주요 경영진으로 판단하고 있으며, 당분기 및 전분기 중 주요 경영진에 대한 보상금액은 다음과 같습니다.\n(단위:천원)\n구\xa0 분\n당분기\n전분기\n3개월\n누적\n3개월\n누적\n단기종업원급여\n831,617\n2,943,570\n1,071,995\n2,792,107\n퇴직급여\n122,024\n366,072\n121,929\n365,787\n합 계\n953,641\n3,309,642\n1,193,924\n3,157,894\n']"
